Papers/PMID:29907916
The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.
Inflammopharmacology2018The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
melatonin — decreases C-reactive protein concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders.”
Quoted verbatim from The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome or related disorders
melatonin — decreases interleukin-6 concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders.”
Quoted verbatim from The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome or related disorders